- Benzinga•7 days ago
DexCom, Inc. (NASDAQ: DXCM ) disclosed Friday that the FDA's panel of the Clinical Chemistry and Clinical Toxicology Devices voted in favor of its planned non-adjunctive indication for its G5 Mobile CGM ...
- The Wall Street Journal•7 days ago
DexCom Inc. shares rose Friday after a U.S. Food and Drug Administration panel voted in favor of the company’s proposed non-adjunctive indication for a glucose-monitoring system.
|Bid||91.20 x 300|
|Ask||91.27 x 100|
|52wk Range||47.92 - 103.29|
|Day's Range||89.70 - 91.44|
|Avg Vol (3m)||951,922|
As of 12:10 PM EDT. NasdaqGS Real Time Price. Market open.